Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEEK-02 neoadjuvant tislelizumab chemo-immunotherapy vs chemo-radiotherapy-immunotherapy in esophageal squamous cell carcinoma
ChiCTR2400091797Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Pathological complete response rate after neoadjuvant therapy combined with immunotherapy. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400091797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091797.